Suppliers and packagers for STRIBILD

STRIBILD

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Gilead Sciences Inc	STRIBILD	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	203100	NDA	Gilead Sciences, Inc.	61958-1201-1	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-1201-1)	2012-08-27

Stribild Drug Supply Chain Analysis

Last updated: February 19, 2026

Stribild, a single-tablet regimen for HIV treatment, relies on a complex global supply chain involving multiple active pharmaceutical ingredients (APIs) and critical excipients. Key suppliers for Stribild components include those manufacturing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (TDF). The manufacturing of these APIs is concentrated among a limited number of specialized chemical and pharmaceutical manufacturers, with significant production capacity located in Asia, particularly China and India.

Who are the Primary API Manufacturers for Stribild Components?

The primary active pharmaceutical ingredients (APIs) in Stribild are elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (TDF). Each API has specific manufacturing pathways and key suppliers.

• Elvitegravir: This integrase strand transfer inhibitor is a complex molecule. Its manufacturing involves multi-step organic synthesis. Major producers of elvitegravir API often possess advanced organic chemistry capabilities. Companies with expertise in complex API synthesis are typically involved. While specific supplier names are often proprietary and subject to change based on contracts and regulatory approvals, large-scale chemical manufacturers with pharmaceutical API divisions are the likely sources.
• Cobicistat: A pharmacokinetic enhancer, cobicistat is another API requiring sophisticated chemical synthesis. Its production also involves specialized chemical processes. The supplier base for cobicistat is similar in nature to that of elvitegravir, focusing on manufacturers with strong organic synthesis and regulatory compliance for API production.
• Emtricitabine: This nucleoside reverse transcriptase inhibitor (NRTI) is a well-established API with a broader supplier base compared to the novel small molecules elvitegravir and cobicistat. However, high purity and consistent quality are paramount for pharmaceutical applications. Manufacturers of nucleoside analogs are the primary suppliers.
• Tenofovir Disoproxil Fumarate (TDF): Another NRTI, TDF is a prodrug of tenofovir. Its synthesis is also a complex chemical process. Suppliers for TDF are generally large API manufacturers with significant capacity and experience in producing antiretroviral drug components.

The geographical concentration of API manufacturing for these components is notable. China and India host a substantial portion of the global API production capacity, including for complex molecules like elvitegravir and cobicistat, and established NRTIs like emtricitabine and TDF. This concentration presents both cost advantages and potential supply chain risks.

What are the Key Excipients and Their Suppliers?

Beyond the APIs, Stribild contains several excipients that are crucial for tablet formulation, stability, and bioavailability. These include binders, disintegrants, fillers, lubricants, and coating agents.

• Cellulose Derivatives: Microcrystalline cellulose (MCC) and hydroxypropyl methylcellulose (HPMC) are common fillers and binders in tablet formulations. Suppliers for these excipients are large chemical companies specializing in cellulose ethers and derivatives. Examples include Ashland, DuPont, and Shin-Etsu Chemical.
• Croscarmellose Sodium: This superdisintegrant aids in tablet breakup. Manufacturers of croscarmellose sodium are typically specialized chemical companies.
• Magnesium Stearate: A lubricant, magnesium stearate prevents tablet sticking to manufacturing equipment. A wide range of chemical suppliers produce pharmaceutical-grade magnesium stearate.
• Titanium Dioxide: Used as an opacifier and for coating. Major global pigment manufacturers supply pharmaceutical-grade titanium dioxide.

The supply chain for excipients is generally more fragmented than for APIs, with a larger number of qualified suppliers globally. However, maintaining consistent quality and regulatory compliance across all excipient sources is essential.

How is the Stribild Supply Chain Regulated?

The supply chain for Stribild is subject to stringent regulatory oversight by health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• API Manufacturing Sites: API manufacturing facilities must comply with current Good Manufacturing Practices (cGMP) standards. Regular inspections by regulatory agencies are conducted to ensure adherence to quality and safety protocols. These inspections cover facility design, equipment, personnel, raw material control, production processes, and quality control testing.
• Drug Product Manufacturing: The formulation of Stribild into finished tablets occurs at dedicated drug product manufacturing sites. These sites also operate under cGMP and are subject to regulatory inspections. The quality of incoming APIs and excipients is rigorously tested.
• Quality Agreements: Pharmaceutical companies manufacturing Stribild enter into detailed quality agreements with their API and excipient suppliers. These agreements define responsibilities for quality control, change management, handling of deviations, and supply chain security.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, such as ICH Q7 for API manufacturing and ICH Q10 for Pharmaceutical Quality Systems, provide a framework for global regulatory compliance.
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory authorities. These confidential documents provide detailed information about the API manufacturing process, facility, and quality controls. Pharmaceutical companies reference these DMFs in their drug applications.
• Supply Chain Security and Traceability: Regulations increasingly focus on ensuring the security and traceability of the pharmaceutical supply chain to prevent counterfeiting and diversion. This involves serialization and tracking of drug products from manufacturing to the end consumer.

The regulatory landscape requires robust quality management systems and transparent communication throughout the supply chain. Any deviation or non-compliance at any stage can lead to significant disruptions, including product recalls and manufacturing suspensions.

What are the Potential Risks and Mitigation Strategies in the Stribild Supply Chain?

The Stribild supply chain, like many complex pharmaceutical supply chains, faces several inherent risks.

• Geopolitical and Economic Instability: The concentration of API manufacturing in specific regions, particularly Asia, makes the supply chain vulnerable to geopolitical tensions, trade disputes, and economic downturns in those areas.
  • Mitigation: Diversifying supplier bases across different geographical regions, where feasible, can reduce dependence on a single country or region. Building stronger relationships with key suppliers and monitoring geopolitical developments proactively are also crucial.
• Raw Material Shortages and Price Volatility: The availability and cost of key starting materials and reagents used in API synthesis can fluctuate. Supply disruptions for these precursor chemicals can impact API production.
  • Mitigation: Maintaining safety stock of critical raw materials, qualifying alternative suppliers for precursors, and engaging in long-term supply contracts can help manage price volatility and ensure availability.
• Quality Control Failures and Regulatory Non-Compliance: A single quality issue or cGMP violation at an API manufacturing site can halt the supply of a critical component. Recalls due to quality defects can have severe financial and reputational consequences.
  • Mitigation: Implementing rigorous supplier qualification programs, conducting regular audits of manufacturing sites, and establishing robust quality agreements are essential. Investing in advanced analytical testing and quality oversight at multiple points in the supply chain provides an additional layer of assurance.
• Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises (e.g., COVID-19) can disrupt manufacturing operations, logistics, and transportation networks.
  • Mitigation: Developing business continuity plans that include alternative logistics routes, backup manufacturing capabilities (if possible through contract manufacturing organizations), and maintaining sufficient inventory levels of finished product and critical raw materials can enhance resilience.
• Intellectual Property (IP) and Counterfeiting: Ensuring the integrity of the supply chain against counterfeit APIs or finished products is critical for patient safety and brand protection.
  • Mitigation: Implementing track-and-trace technologies, serialization of product batches, and vigilant monitoring of distribution channels help to combat counterfeiting. Strong legal frameworks and cooperation with law enforcement are also important.

Effective supply chain management requires continuous risk assessment, proactive planning, and close collaboration with all supply chain partners.

What is the Market Landscape for Stribild and Its Generic Equivalents?

Stribild was developed by Gilead Sciences. Its patent expiry and the subsequent emergence of generic versions have significantly altered its market landscape.

• Original Innovator: Gilead Sciences held the original patents for Stribild. As patents expire, the exclusivity period ends, opening the market to generic competition.
• Generic Competition: Following patent expiries in major markets, generic manufacturers began producing and marketing their own versions of Stribild. This typically leads to a substantial decrease in the price of the drug.
  • Key Generic API Suppliers: The suppliers of APIs for generic Stribild often differ from those for the originator product. Generic manufacturers frequently source APIs from cost-effective manufacturers, predominantly located in India and China, who have established capabilities in producing high-volume antiretroviral APIs.
  • Contract Manufacturing Organizations (CMOs): Many generic drug companies outsource API manufacturing and/or drug product formulation to CMOs. These CMOs possess specialized manufacturing expertise and infrastructure.
• Market Dynamics: The introduction of generics increases competition, driving down prices and expanding access to treatment, particularly in low- and middle-income countries. The demand for Stribild ingredients from generic manufacturers contributes to the overall market for these APIs.
• Regulatory Approvals for Generics: Generic versions must undergo bioequivalence studies and receive regulatory approval from agencies like the FDA and EMA before they can be marketed. This process ensures that the generic product is therapeutically equivalent to the reference listed drug.

The market for Stribild and its generic equivalents is dynamic, influenced by patent expiries, regulatory approvals, pricing strategies, and global health initiatives aimed at increasing access to HIV treatment. The supply chains for generic versions are often managed with a primary focus on cost-efficiency while maintaining stringent quality standards.

Key Takeaways

The supply chain for Stribild is characterized by a concentration of API manufacturing for its unique components (elvitegravir, cobicistat) in Asia, primarily China and India. While excipient supply is more diversified, rigorous quality control and regulatory compliance are paramount across all supplier tiers. Geopolitical instability, raw material shortages, quality failures, and natural disasters represent significant risks, necessitating proactive mitigation strategies such as supplier diversification, maintaining safety stocks, and robust quality agreements. The market landscape has shifted from innovator exclusivity to robust generic competition, increasing demand for cost-effective API suppliers globally and expanding treatment access.

FAQs

1. How does the geographical concentration of API manufacturing for Stribild impact supply chain resilience?

A concentrated API manufacturing base, particularly in regions like China and India, exposes the Stribild supply chain to heightened risks from geopolitical events, trade disputes, and localized disruptions (e.g., environmental regulations, natural disasters). Mitigation strategies include dual sourcing from different regions, establishing strategic inventory reserves of APIs and critical raw materials, and fostering strong, long-term relationships with key suppliers to gain priority during shortages.

2. What are the primary regulatory requirements for API suppliers in the Stribild supply chain?

API suppliers must adhere to stringent current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies such as the FDA and EMA. This includes robust quality management systems, validated manufacturing processes, rigorous testing of raw materials and finished APIs, and meticulous record-keeping. Suppliers often submit Drug Master Files (DMFs) to regulatory agencies detailing their manufacturing operations.

3. How has the emergence of generic Stribild variants influenced its API supply chain?

The introduction of generic Stribild has broadened the supplier base for its APIs. Generic manufacturers often seek out multiple, cost-competitive API sources, predominantly from India and China, which have developed large-scale manufacturing capabilities for antiretrovirals. This competition can drive down API prices but also necessitates enhanced due diligence by generic drug companies to ensure consistent quality from a wider array of suppliers.

4. What measures are in place to ensure the quality and authenticity of Stribild APIs and finished products?

Quality assurance involves a multi-faceted approach. Pharmaceutical companies establish strict supplier qualification processes, conduct regular audits of manufacturing facilities, and implement robust quality agreements. At the finished product level, serialization and track-and-trace technologies are increasingly employed to enhance supply chain security and prevent the introduction of counterfeit products. Incoming API batches undergo comprehensive testing before being used in formulation.

5. Are there specific sustainability considerations for Stribild's API and excipient suppliers?

While not always explicitly detailed in public domain for specific drugs, pharmaceutical companies are increasingly prioritizing sustainability in their supply chains. This can include evaluating suppliers on their environmental practices, waste management, energy consumption, and adherence to ethical labor standards. Companies may also look for suppliers who utilize greener chemistry principles in their manufacturing processes. These factors are becoming more integrated into supplier selection and auditing protocols.

Citations

[1] Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-regulation/good-manufacturing-practice-gmp

[2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/scientific-advice/good-manufacturing-practice

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/products/guidelines

[4] Gilead Sciences. (2023). Stribild® (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) Tablets. Retrieved from https://www.gilead.com/medicine/hiv/stribild